The same pharmacogenomics that sits on our condition pages, read from the other end. People rarely arrive asking about SLCO1B1 — they arrive having been prescribed a statin. Each page below collects what published guidelines say about one drug, names the genes involved, and links to the variants your own file would contain.
Supplements — kept apart, with the evidence stated on each →
None of this is dosing guidance. Where a clinical guideline exists it is written for prescribers, and the pages say so. Nothing here is a reason to start, stop or change a medication.
Fluorouracil and capecitabine, the backbone of colorectal cancer treatment. One enzyme clears most of the dose, and the small number of people who lack it can be harmed severely by an ordinary dose.
DPYD
See what the research says → ChemotherapyThe enzyme that disposes of its active metabolite is the same one behind Gilbert syndrome — a harmless quirk of bilirubin that turns into a dosing problem the moment this drug is prescribed.
UGT1A1
See what the research says →The same pharmacogenomics already published on our condition pages, read from the drug side instead: what published guidelines say about one medicine, which genes are involved, and the variants your own file would contain.
No. Where a clinical guideline exists it is written for prescribers, and nothing here is a reason to start, stop or change a medication — that belongs with the clinician or pharmacist managing treatment.
Because almost nothing sold as a supplement has a prescribing guideline behind it the way a drug does, and listing the two together would lend the second the authority of the first.
By gene symbol as a whole word, gathered from the pgx_notes already published on the condition pages that discuss each drug — not a second, separate copy of that information.